Immunotherapy drug pembrolizumab shows promise for mesothelioma patients
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the ...
Apr 20, 2015
0
7